Polatuzumab-Based Combination Continues to Impress in Real-World DLBCL Analyses

(MedPage Today) — At the recent American Society of Hematology annual meeting, real-world analyses examined how polatuzumab vedotin (Polivy) with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) is being adopted outside of…